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In this work, we used a preparation of diminazene, which 
belongs  to  the  group  of  aromatic  diamidines.  This 
compound acts on the causative agents of blood protozoan 
diseases produced by both flagellated protozoa (Trypanosoma) 
and members of the class Piroplasmida (Babesia, Theileria, 
and Cytauxzoon) in various domestic and wild animals, and 
it is widely used in veterinary medicine. We examined the 
behavior  of  water-disperse  diminazene  (immobilized  in 
Tween 80 micelles) at the cellular and organismal levels. We 
assessed the interaction of an aqueous and a water-disperse 
preparation with cells of the reticuloendothelial system. We 
compared the kinetic parameters of aqueous and water- 
disperse diminazene in sheep erythrocytes and plasma. The 
therapeutic properties of these two preparations were also 
compared.  We  found  that  the  surface-active  substances 
improved intracellular penetration of the active substance 
through interaction with the cell membrane. In sheep blood 
erythrocytes, micellar diminazene accumulated more than 
its  aqueous  analog.  This  form  was  also  more  effective 
therapeutically  than  the  aqueous  analog.  Our  findings 
demonstrate  that  use  of  micellar  diminazene  allows  the 
injection dose to be reduced by 30%.
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Introduction
Increasing the effectiveness of targeted drug delivery is 
an important issue in biomedicine and is an area of active 
and intense research [10]. In drug manufacturing, 
polymers and surface-active substances (SASs) are 
extensively used as auxiliary components (e.g., substances 
that prolong drug action and emulsifiers). In the past few 
years, research has shown that these may serve as a basis 
for the development of effective targeted delivery systems 
for high- and low-molecular weight compounds [1,3,5,9, 
15].
Currently, one of the most active areas of research in 
veterinary medicine is the construction of drugs based on 
vesicular (micelles and liposomes) or similar (dendrimers 
and fullerenes) nanosystems. Micellar and liposomal 
corpuscular systems are similar in structure and delivery 
properties and permit intraorganismal and intracellular 
delivery of markedly hydrophobic drugs [11]. At times, the 
introduction of an active substance into such a system 
enhances drug bioavailability; this subsequently increases 
the therapeutic activity and allows the use of lower drug 
doses. The resulting preparations are often less toxic and 
have greater therapeutic effectiveness.
Micelles are aggregates formed by long-chain diphilic 
molecules or SAS ions. These aggregates form spon-
taneously in solutions containing these molecules when a 
specific concentration, called the critical concentration of 
micelle formation (CCMF), is reached. The CCMF is 
primarily dependent on the nature of the polar group and on 
the length of the molecular chain [14]. At SAS con-
centrations close to the concentration termed CCMF1, 
micellar particles are formed in which the inner areas are 
created by the hydrophobic portions of SAS molecules, 
with hydrophilic portions concentrated at the surface. As 
the SAS concentration increases, the micelles become 
polymorphic (globular, cylindrical, or hexagonal) and 
form more complex shapes [17].
Among the wide variety of anti-parasitic veterinary 
drugs, anti-piroplasm agents deserve particular attention. 
Piroplasms are protozoa that destroy blood cells (primarily 
erythrocytes), thereby causing oxygen starvation in the 
affected organisms. These microorganisms are extremely 
damaging in animal husbandry and are the causative agent 
of piroplasmosis, a major disease in tropical and sub-304    Sergey A. Staroverov et al.
tropical regions that threatens more than 600 million 
animals.
Piroplasms are transmitted by ticks and include the 
genera  Babesia and Theileria (syn. Cytauxzoon). The 
asexual reproduction of these microorganisms occurs in 
blood stem cells (Babesia) and lymphoid cells (Theileria). 
Sexual reproduction and sporulation is carried out in the 
body of the transporting host (tick). Piroplasms also are 
transmitted transovarially.
Occasional cases of human piroplasm infection in the 
United States and Europe are associated with Babesia 
microti and Babesia divergens, which are transmitted by 
Ixodes ticks [16]. In the southern regions of Russia, three 
outbreaks of cattle piroplasmosis and francisellosis as well 
as horse nutalliosis occur, usually from April until October. 
In southwestern Russia, cases of cattle babesiosis have 
been recorded in the spring. This occurrence can be 
explained by inadequate prophylactic measures for the 
control of transmitter ticks, and also by increases in tick 
populations caused by sudden changes in solar activity. 
The anti-piroplasm reagents most commonly admini-
stered in veterinary medicine are diminazene aceturate 
[2,6,7] and berenil (a mixture of diminazene aceturate and 
antipyrine). In 1958, diminazene was resynthesized in the 
USSR and named azidine. The purpose of our study was to 
examine the biodynamics of micellar diminazene. We 
assessed the effectiveness of this form of the drug in terms 
of intracellular drug localization and selective accumula-
tion at the sites of infectious agent aggregation.
Materials and Methods
Materials
Trizma base and 3-sn-phosphatidylcholine were purchased 
from Fluka Chemie AG (Switzerland). RPMI 1640 
medium and fetal calf serum were obtained from Sigma 
(USA). Diminazene aceturate was purchased from 
Transchem Ltd. (India). Neozidin M (ZAO Nita-Farm, 
Russia) was used as a micellar diminazene preparation.
Methods
In this study, aqueous and micellar forms of diminazene 
were used. Aqueous diminazene was administered to 
experimental animals at a therapeutic dose (3.5 mg/kg 
body weight) as recommended by the manufacturer. 
Micellar diminazene was prepared in the following solution: 
5% antipyrine, 5% diminazene benzoate, 50% dimethy-
lacetamide, 17% Tween 80, 5% polyvinylpyrrolidone 
(PVP) 12PF, 1% benzyl alcohol, and 17% distilled water. 
Detailed descriptions of the procedure used to prepare the 
stable water-disperse form of diminazene benzoate [18] 
and to assess its effectiveness have been given previously 
[19]. Experimental animals chosen by the analogy 
principle, consisting in choosing animals of the same sex, 
age, and weight that were reared under the same 
conditions. Experimental animals (Stavropol Merino 
mongrel sheep) were divided into two groups of three 
sheep each (body weight 35 to 40 kg; age 1.5 to 2 years). 
Group 1 received micellar diminazene at a dose of 1 mL per 
20 kg (2.5 mg/kg body weight). Group 2 received a 7% 
solution of diminazene aceturate at a dose of 1 mL per 20 
kg (3.5 mg/kg body weight). 
Blood samples were collected from the jugular vein at 
0.5, 2, 4, 6, 8, 24, and 48 h after drug administration. The 
blood was separated into plasma and erythrocytes by 
centrifugation (1,000 × g for 15 min). The concentration 
of diminazene was measured in both fractions. The 
diminazene concentration in blood plasma was determined 
by spectrophotometer (Cary 100; Varian, USA) using the 
method described by Klatt and Hajdu [8].
Therapeutic efficiency
The animal experiments were conducted on two farms 
and in two veterinary clinics located in three different 
regions of Stavropol Territory, Russia, where babesiosis is 
endemic.
The effectiveness of the preparation for treating sheep 
babesiosis caused by Babesia bigemiuna was assessed 
during the spring infection outbreaks of 2003 and 2005.
Altogether, we evaluated 1,281 animals in our study 
including 246 that were treated for therapeutic purposes 
and 1,035 that were treated prophylactically. The sheep 
belonged to different age-sex groups. Babesiosis in the 
sheep included in our study was diagnosed according to 
epizootological and clinical data, xenodiagnostic results, 
and the findings from a laboratory study of peripheral 
blood smears. For diagnosing babesiosis, blood was 
collected from the ear vein, and the smears were made with 
the first drops. The smears were air-dried, fixed in 96% 
alcohol, and stained by the Romanovsky-Gimza method 
[12].
The piroplasmicidal effectiveness of neozidin M was 
tested by using a 5% variant. The novel (micellar) form of 
diminazene was administered to all animals at a 
concentration of 1 mL per 20 kg of body weight or 2.5 
mg/kg diminazene (the active substance).
Intracellular penetration of the water-soluble and 
micellar forms of diminazene
Rat peritoneal macrophages were isolated by a conven-
tional method [4]. We used Tween 80 as a nonionic SAS, 
which was conjugated to fluorescein isothiocyanate 
(FITC) as described by Storz [20]. According to the quality 
certificate supplied by the manufacturer, the CCMF1 value 
for this SAS was 1.5 × 10
򰠏4 M.
Diminazene in rat peritoneal macrophages was identified 
by using an indirect immunochemical method with phage 
(primary, 1 × 10
13 phage particles/mL), rabbit anti-phage Diminazene accumulation in cells and in organs    305
Fig. 1. Rat peritoneal cells cultured with FITC-labeled SAS 
micelles (green). ×400.
Fig. 2. Rat peritoneal cells cultured in the presence of micellar 
diminazene. ×400.
Fig. 3. Rat peritoneal cells cultured in the presence of aqueous 
diminazene. ×400.
(secondary, 1 : 500), and goat anti-rabbit FITC-labeled 
(tertiary; Fluka, Japan) antibodies.
Mini-antibody clones specific for diminazene were 
selected by using a sheep combinatorial phage library 
kindly provided by Professor W. J. Harris, University of 
Aberdeen, Aberdeen, UK. Fluorescence analysis with a 
DM LB fluorescence microscope (Leica, Germany) was 
used to visualize green FITC fluorescence, which 
indicated the presence of diminazene at the site being 
examined. This test was also used to detect Tween 80 
(which had also been conjugated with FITC) on the surface 
of and inside the rat peritoneal cells.
The peritoneal cells were prepared for microscopy by the 
following method. Smears were made from 50 μL of a cell 
suspension. The smears were washed with cold acetone, 
air-dried, and then washed with phosphate buffered saline 
(PBS; pH 7.2). After that, the smears were incubated for 1 
h in a suspension of specific phage anti-diminazene 
antibodies diluted in PBS to 1 × 10
13 phage particles/mL. 
The smears then were washed with PBS, incubated for 1 h 
with a solution of rabbit antiphage antibodies that were 
diluted 1 : 500 in PBS, and washed with PBS. Finally, the 
smears were incubated for 1 h with a solution of 
FITC-labeled anti-rabbit antibodies (diluted 1 : 100 in 
PBS) and were washed with PBS. After drying, the smears 
were analyzed with a DM LB fluorescence microscope.
Results
Intracellular penetration of the water-soluble and 
micellar forms of diminazene
It is known that SASs promote micelle formation and 
drug stability. Therefore, it was important to conduct 
experiments to evaluate the interaction of Tween 80 with 
peritoneal cells. Fig. 1 shows peritoneal macrophage cells 
cultured in the presence of FITC-labeled Tween 80. The 
green fluorescence observed on and inside the cells 
suggests that the SAS accumulated in the cytoplasm after 
passing through the cell membrane (the nuclei appear 
yellow). The presence of diminazene in the peritoneal cells 
was observed by using mini-antibodies. Figs. 2 and 3 show 
the immunochemical detection of diminazene in the cells, 
in which the compound appears as green fluorescence 
owing to the formation of a complex between diminazene 
and the mini-antibodies.
Pharmacokinetic  parameters  of  specific  forms  of 
diminazene
The pharmacokinetic parameters of specific forms of 
diminazene depend on its chemical properties and the 
mode of administration. Intramuscular injection of water- 
soluble diminazene results in a sufficiently rapid increase 306    Sergey A. Staroverov et al.
Fig. 4. Kinetic parameters of intramuscularly injected aqueous 
and micellar diminazene in sheep plasma. 
Fig. 5. Kinetic parameters of intramuscularly injected aqueous 
and micellar diminazene in sheep blood erythrocytes.
of the drug concentration in blood. The pharmacokinetic 
curve is described by a two-chamber model in which the 
drug concentration often falls below the therapeutic level 
in the second phase.
In this study, the maximal concentration of aqueous 
diminazene in sheep plasma was 16.86 μg/mL (30 min). 
The half-life of diminazene was 10 ± 1.5 h. The concen-
tration of micellar diminazene also peaked at 30 min after 
administration, but the maximal value was much lower 
(2.97 μg/mL). The half-life of the drug was 4 ± 1.5 h. With 
both forms of the drug, 97% of the administered dose was 
eliminated from the animals within 96 h (Fig. 4).
A substantially different pattern of diminazene 
accumulation and elimination was observed when the drug 
concentration was measured in erythrocytes (Fig. 5). For 
micellar diminazene, two concentration peaks were 
recorded: 2.1 μg/mL at 2 h after administration and 2.4 
μg/mL after 22 h. The kinetics of changes in aqueous 
diminazene concentrations in sheep erythrocytes were the 
same as those for plasma with a peak concentration of 1.87 
μg/mL recorded at 4 h after drug administration.
Therapeutic efficiency
The therapeutic effects were observed after 10 to 14 h. 
After 24 h, the animal body temperature decreased to 
normal and appetite was restored. No blood protozoa were 
detected when the blood smears were examined at 1 to 2 
days after treatment. No side effects or complications were 
recorded.
For comparison, we used the preparation veriben (CEVA 
Santé Animale, France), which was administered as a 7% 
solution at a concentration of 3.5 mg/kg of body weight. 
We did not observe any statistically significant differences 
in therapeutic effectiveness between the preparations. 
However, the dosage of the micellar form was significantly 
lower (by 30%), and apparently decreased the adverse side 
effects of the preparation.
Discussion
Despite the favorable prospects for using micelles as an 
active component for the delivery of injectable drugs 
containing hydrophobic substances [13,21], the biological 
properties of micelles are poorly understood. This is 
especially true for the biodynamics of micellar systems and 
their ability to interact with cellular structures. Therefore, 
we examined the in vitro interaction of micelles formed 
with diminazene and Tween 80 with cells. We subsequently 
performed experiments to detect diminazene and Tween 80 
in the intracellular space. In the rat peritoneal cells, 
diminazene delivered via both micellar and water-soluble 
systems can be observed (green-yellow fluorescence of the 
cells). In the control cells (rat peritoneal cells cultured 
without diminazene), no fluorescence was observed (data 
not shown). Considering that Tween 80 can accumulate on 
the cell surface and penetrate into the cells, we presume 
that this reagent also facilitates diminazene delivery into 
the cells by changing membrane permeability.
We next determined the distribution of micellar and 
aqueous diminazene in blood plasma and erythrocytes 
according to pharmacokinetic parameters. We assumed 
that the penetration of SASs through the cell membrane 
might permit more active accumulation of the drug in the 
erythrocytes. Our results show that micellar diminazene 
accumulated in the erythrocytes more actively than did the 
aqueous form of the drug. These findings indicate that the 
micellar form is likely to promote higher therapeutic 
effectiveness of the drug. To assess the effectiveness, we 
performed a number of trials.
When analyzing the epizootological data, we accounted 
for the distribution area of the specific ticks (transmitters of 
the disease), the season, and the disease prevalence in the Diminazene accumulation in cells and in organs    307
region. The xenodiagnostic results showed that large numbers 
of pasture ticks (transmitters of Babesia) belonging to the 
genera Boophilus, Ixodes, and Hyalomma were found on 
the animals. The clinical symptoms included anorexia, 
depression, brachycardia, proventricular atony, a body 
temperature increase of 1.5 to 2
oC, and hemoglobinuria (in 
severe cases). A final diagnosis of a particular blood 
protozoan disease was made after observing the 
characteristic paired pear-shaped forms of endoglobular 
parasites in the peripheral blood smears.
In summary, the findings from the present study demonstrate 
that micellar diminazene has pharmacokinetic charac-
teristics that indicate the ability of this form of the drug to 
effectively penetrate into erythrocytes. This results in the 
subsequent drug accumulation at the sites of infectious 
agents. Further research on this drug form is recommended 
to explore its wider application in veterinary parasitological 
practice.
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